How do fluconazole and posaconazole interact with apixaban (Eliquis), and what dose adjustments are recommended?

Fluconazole vs Posaconazole Interaction with Apixaban (Eliquis)

Posaconazole requires a 50% dose reduction of apixaban (from 5mg to 2.5mg twice daily), while fluconazole does not require routine dose adjustment despite being a moderate CYP3A4/P-gp inhibitor.

Key Mechanistic Differences

Apixaban is metabolized via both CYP3A4 and P-gp pathways. The critical distinction between these azoles lies in their inhibitory potency:

• Posaconazole is classified as a combined strong CYP3A4 and P-gp inhibitor 1
• Fluconazole is a moderate CYP3A4 inhibitor with weaker P-gp effects 2, 3

Dosing Recommendations

For Posaconazole + Apixaban:

If patient is on apixaban 5mg or 10mg twice daily:

• Reduce apixaban dose by 50% (e.g., 5mg becomes 2.5mg twice daily) 1
• This applies to all standard dosing regimens for atrial fibrillation and VTE treatment

If patient is already on apixaban 2.5mg twice daily:

• Avoid the combination entirely 1
• Consider alternative antifungal or anticoagulant

Recent transplant data confirms this approach: reduced-dose apixaban (2.5mg twice daily) with posaconazole resulted in median trough levels of 124 ng/mL, which falls within the expected therapeutic range of 34-230 ng/mL 4. This validates the 50% dose reduction strategy.

For Fluconazole + Apixaban:

No routine dose adjustment required 2

The evidence supporting this is multifaceted:

• A 2022 retrospective cohort study of 216 hospitalized patients found no statistically significant increase in bleeding risk after adjusting for confounders (adjusted OR 1.71,95% CI 0.85-3.40) 5
• However, a 2022 Danish nationwide study specifically in atrial fibrillation patients showed apixaban users had increased bleeding risk with systemic fluconazole (OR 3.5,95% CI 1.4-10.6), while rivaroxaban and dabigatran users did not 6

Clinical Algorithm

When prescribing azoles with apixaban:

1. Identify the azole:

   • Posaconazole or itraconazole → Strong inhibitor pathway
   • Fluconazole → Moderate inhibitor pathway

2. For posaconazole/itraconazole:

   • Check current apixaban dose
   • If 5mg or 10mg BID → Reduce by 50%
   • If 2.5mg BID → Avoid combination or switch agents
   • Consider therapeutic drug monitoring (TDM) if available 4

3. For fluconazole:

   • Continue standard apixaban dosing
   • Increase bleeding surveillance in high-risk patients (elderly, low hemoglobin, multiple antiplatelet agents)
   • Monitor for bleeding symptoms during first 30 days 6
   • Consider dose reduction only if patient has ≥2 additional bleeding risk factors 3

Important Caveats

Fluconazole considerations:

• While no routine dose adjustment is recommended, the Danish study suggests real-world bleeding risk exists specifically with apixaban 6
• This risk appears unique to apixaban compared to other DOACs
• Patients on concomitant antiplatelet therapy face compounded risk (aspirin increased bleeding from 1.8% to 3.4% per year with apixaban) 1
• Topical azoles do not increase bleeding risk 6

Posaconazole considerations:

• The interaction is predictable and dose-dependent 4
• Therapeutic drug monitoring of apixaban is encouraged when available to individualize dosing 4
• The European guidelines classify posaconazole as "orange" (consider dose adjustment) for apixaban, reflecting moderate interaction potential 3

Avoid these combinations entirely:

• Apixaban 2.5mg BID + any strong CYP3A4/P-gp inhibitor 1
• Apixaban + strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) 1